- Home
- Publications
- Publication Search
- Publication Details
Title
Venetoclax in the treatment of chronic lymphocytic leukemia
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 15, Issue 5, Pages 353-366
Publisher
Informa UK Limited
Online
2019-04-10
DOI
10.1080/17425255.2019.1606211
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
- (2018) Steven Coutre et al. BLOOD
- High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies
- (2018) Peter Dreger et al. BLOOD
- The rise of apoptosis: targeting apoptosis in hematologic malignancies
- (2018) Rebecca Valentin et al. BLOOD
- Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2018) Matthew S. Davids et al. CLINICAL CANCER RESEARCH
- Venetoclax: A new wave in hematooncology
- (2018) Jana Mihalyova et al. EXPERIMENTAL HEMATOLOGY
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- BCL-2 as therapeutic target for hematological malignancies
- (2018) Guilherme Fleury Perini et al. Journal of Hematology & Oncology
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BCL-2 in Hematologic Malignancies
- (2018) Nadia Khan et al. Targeted Oncology
- Potential of BCL2 as a target for chronic lymphocytic leukemia treatment
- (2018) Riccardo Moia et al. Expert Review of Hematology
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
- (2018) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Venetoclax for the treatment of chronic lymphocytic leukemia
- (2017) Massimo Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia
- (2017) Pawel Robak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- Pathways and mechanisms of venetoclax resistance
- (2017) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin
- (2017) Manoj S. Chiney et al. XENOBIOTICA
- The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
- (2017) Benjamin L. Lampson et al. Current Hematologic Malignancy Reports
- Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis
- (2016) Aksana K. Jones et al. AAPS Journal
- Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base
- (2016) Alina M. Mateo et al. ANNALS OF SURGICAL ONCOLOGY
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
- (2016) M. A. Anderson et al. BLOOD
- The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
- (2016) Matthew D. Blunt et al. CLINICAL CANCER RESEARCH
- Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
- (2016) AW Roberts et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis
- (2016) L. Grosse et al. EMBO JOURNAL
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
- (2016) Johanna Weiss et al. Pharmaceutics
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study
- (2015) J. Donato et al. BLOOD
- Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly
- (2015) Anna Korycka-Wołowiec et al. Expert Opinion on Drug Metabolism & Toxicology
- A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
- (2015) Thomas J. Kipps et al. LEUKEMIA & LYMPHOMA
- An interconnected hierarchical model of cell death regulation by the BCL-2 family
- (2015) Hui-Chen Chen et al. NATURE CELL BIOLOGY
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
- (2013) Meike Vogler et al. BRITISH JOURNAL OF HAEMATOLOGY
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Overview of P-glycoprotein inhibitors: a rational outlook
- (2012) Kale Mohana Raghava Srivalli et al. Brazilian Journal of Pharmaceutical Sciences
- Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia
- (2011) Pooja P Advani et al. Expert Opinion on Drug Metabolism & Toxicology
- Apoptotic cell signaling in cancer progression and therapy
- (2011) Jessica Plati et al. Integrative Biology
- An overview of chronic lymphocytic leukaemia biology
- (2010) M.T.S. Bertilaccio et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Diagnostic issues in chronic lymphocytic leukaemia (CLL)
- (2010) Estella Matutes et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- BH3-only proteins: Orchestrators of apoptosis
- (2010) Aisha Shamas-Din et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search